Cabergoline
It is a long acting dopamine receptor agonist with a high affintity for D2 receptors, but having low affinity for dopamine D1, a1, a2 adrenergic and 5-HT1 and 5-HT2 serotonin receptors. It directly inhibits prolactin levels.Hyperprolactinemic disorders either an idiopathic or due to pituitary adenomas.
Administered orally. No interference by concomitant food intake. Starting intial dose is 0.25mg twice weekly. Dose may be increased in increment of 0.25mg every four weeks as needed, according to body prolactin levels, upto 1mg twice a week. Discontinue the drug only when a normal serum prolactin level has been maintained for 6-months.
Hypersensitivity to Cabergolin or other ergot alkaloid. Uncontrolled hypertension.
Untreated hypertension or pregnancy induced hypertension (preeclampsia and eclampsia), monitor LFTs. Paediatric:Safety and effectiveness not established. Pregnancy and Lactation : Use with caution if clearly indicated. Elderly : Use with caution if clearly indicated.
Allergy, gastrointestinal intolerence, asthenia, fatigue, flu-like syndrome, malaise, hot flushes, edema, weight changes, somnolence, depression, nervousness, anxiety, impaired concentration, very rarely cardiac failure and constructive pericarditis, musculoskeletal pain, respiratory affection, abnormal vision, breast pain, dysmenorrhoea, decreased libido, overdose may produce nasal congestion, syncope or hallucinations.
D2 antagonists such as phenothiazine, butyrophenones, thioxanthenes, metoclopramide, antihypertensives.
